Biotechnology

Techseriesinsight > Blog > News > Biotechnology

February 23, 2026
PRNewswire
Biotechnology, News

Clonell Unveils New Approach to Treat 34 Incurable Diseases

Regenerative Medicine Strategy Targets Root Causes Regenerative cell therapy is at the center of a newly released white paper from Clonell Therapeutics, Inc., outlining treatment models for 34 conditions...

February 23, 2026
PRNewswire
Biotechnology, News

ADC Therapeutics Amends Royalty Financing Agreement with HealthCare Royalty

ADC Therapeutics Royalty Agreement Updated ADC Therapeutics SA has announced an amendment to its existing ADC Therapeutics royalty agreement with entities managed by HealthCare Royalty. The revised terms provide...

February 23, 2026
Business Wire
Biotechnology, News

Zura Bio Appoints Mark Eisner and Ajay Nirula to Board

Zura Bio Board Appointments Strengthen Clinical Leadership The Zura Bio board appointments mark a significant step forward for Zura Bio Limited as the company advances its pipeline in autoimmune...

February 23, 2026
Business Wire
Biotechnology, News

Gilead Sciences to Acquire Arcellx in $7.8B Deal to Advance Anito-cel

Gilead Arcellx Acquisition Announced The Gilead Arcellx acquisition marks a major expansion of Gilead Sciences’ oncology and cell therapy portfolio. Gilead has entered into a definitive agreement to acquire...

February 20, 2026
Business Wire
Biotechnology, News

Seaport Therapeutics Shares GAD Placebo Response Meta-Analysis at ISCTM 2026

Seaport Therapeutics Presents New GAD Findings Seaport Therapeutics presented new data on placebo response in generalized anxiety disorder (GAD) trials. The findings were shared at the International Society for...

February 20, 2026
Business Wire
Biotechnology, News

Sai Life Sciences to Hire 700+ Professionals in FY27 Expansion

Sai Life Sciences hiring FY27 plans signal strong growth in India’s CRDMO sector. Sai Life Sciences announced it will recruit more than 700 scientific, technical, and management professionals during...

February 20, 2026
Business Wire
Biotechnology, News

FDA Accepts Giredestrant NDA for ESR1-Mutated Breast Cancer

Giredestrant NDA has been accepted by the U.S. Food and Drug Administration for review in patients with ESR1-mutated, ER-positive advanced breast cancer. Genentech, a member of the Roche Group,...

February 19, 2026
Business Wire
Biotechnology, News

Brenus Pharma Highlights STC-1010 Data at AACR Immuno-Oncology 2026

Brenus Pharma presented new preclinical and early clinical data on STC-1010 in colorectal cancer at the American Association for Cancer Research Immuno-Oncology (AACR IO) Conference 2026 in Los Angeles...

February 19, 2026
Business Wire
Biotechnology, News

ENHERTU Type II Variation Validated by EMA for HER2 Positive Early Breast Cancer

The ENHERTU Type II Variation application has received validation from the European Medicines Agency (EMA) for use as a post-neoadjuvant treatment in adults with HER2 positive early breast cancer....

February 18, 2026
Business Wire
Biotechnology, News

Sensei Biotherapeutics Acquisition of Faeth and $200M Private Placement

Sensei Biotherapeutics, Inc. has completed the Sensei Biotherapeutics acquisition of Faeth Therapeutics and announced a concurrent $200 million private placement. This strategic move expands Sensei’s oncology pipeline while strengthening...